Penumbra/$PEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Penumbra
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Ticker
$PEN
Sector
Primary listing
NYSE
Employees
4,500
Headquarters
Website
Penumbra Metrics
BasicAdvanced
$9.7B
66.48
$3.74
0.40
-
Price and volume
Market cap
$9.7B
Beta
0.4
52-week high
$310.00
52-week low
$174.23
Average daily volume
476K
Financial strength
Current ratio
6.754
Quick ratio
3.804
Long term debt to equity
15.864
Total debt to equity
17.043
Interest coverage (TTM)
135.88%
Profitability
EBITDA (TTM)
209.745
Gross margin (TTM)
69.08%
Net profit margin (TTM)
11.54%
Operating margin (TTM)
15.05%
Effective tax rate (TTM)
14.76%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
7.50%
Return on equity (TTM)
12.03%
Valuation
Price to earnings (TTM)
66.482
Price to revenue (TTM)
7.496
Price to book
7.46
Price to tangible book (TTM)
8.61
Growth
Revenue change (TTM)
12.92%
Earnings per share change (TTM)
915.21%
3-year revenue growth (CAGR)
16.66%
10-year revenue growth (CAGR)
23.99%
3-year earnings per share growth (CAGR)
92.78%
10-year earnings per share growth (CAGR)
30.96%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Penumbra stock?
Penumbra (PEN) has a market cap of $9.7B as of August 15, 2025.
What is the P/E ratio for Penumbra stock?
The price to earnings (P/E) ratio for Penumbra (PEN) stock is 66.48 as of August 15, 2025.
Does Penumbra stock pay dividends?
No, Penumbra (PEN) stock does not pay dividends to its shareholders as of August 15, 2025.
When is the next Penumbra dividend payment date?
Penumbra (PEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Penumbra?
Penumbra (PEN) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.